64.40p
+0.63%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Niox Group
Its shares trade on LSE under the ticker NIOX.L. It has been listed since 13 March 2014. In the fiscal year to 31 December 2025, it reported revenue of £48.7m and net income of £7.0m. At that date it held total assets of £76.2m and shareholders' equity of £73.7m.
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2014-03-13. The firm is primarily focused on offering its commercialized asthma management products directly to specialist physicians in various markets. The Company’s NIOX products are used to improve asthma and offers a portfolio of asthma and chronic obstructive pulmonary disease product candidates. The Company’s commercialized chronic obstructive pulmonary disease (COPD) products are Tudorza and Duaklir in the United States. The Company’s pipeline products also include late-stage nitric oxide product LungFit PH, which is a ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Mar 2014
- Employees
- 322
- Website
- circassia.com ↗
Leadership
Pay as last reported
- Mr. Ian JohnsonNon-Executive Chairman of the Board, since 2019£851,000
- Mr. Jonathan EmmsChief Executive Officer, Executive Director, since 2019£860,000
- Ms. Sarah DuncanChief Financial Officer, Executive Director, since 2020
- Mr. Nicholas MillsNon-Independent Non-Executive Director£47,000
- Ms. Sharon CurranNon-Executive Independent Director£70,000
- Mr. Robert NaylorNon-Executive Independent Director£34,000
- Mr. Garry WattsSenior Non-Executive Independent Director£74,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 36
- Social
- 66
- Governance
- 54
- Direct emissions (scope 1)
- 0 t
- Energy emissions (scope 2)
- 83 t
- Women in the workforce
- 47%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Circassia Group PLC has a strong portfolio of innovative products in the respiratory and autoimmune disease markets, allowing them to effectively address unmet medical needs.
- The company has a highly skilled and experienced management team, with a track record of successfully developing and commercializing pharmaceutical products.
- Circassia has established strategic partnerships with leading pharmaceutical companies, which provides access to additional resources, expertise, and markets.
Weaknesses
- Circassia Group PLC heavily relies on a limited number of products for its revenue, making it vulnerable to any setbacks or regulatory issues in these products.
- The company operates in a highly competitive market, with potential challenges in pricing, marketing, and gaining market share against larger pharmaceutical companies.
- Circassia has a relatively small market presence compared to its competitors, which may limit its ability to negotiate favorable terms with suppliers or distribution partners.
Opportunities
- The increasing prevalence of respiratory and autoimmune diseases offers a significant growth opportunity for Circassia Group PLC, as there is an expanding patient population in need of effective treatments.
- Expanding into new geographic markets, particularly emerging markets with underpenetrated healthcare systems, could provide additional revenue streams and diversify the company's customer base.
- Advancements in technology and research present opportunities for Circassia to develop and commercialize innovative therapeutics, giving them a competitive edge in the market.
Threats
- The regulatory environment for pharmaceutical companies is complex and subject to change, posing a potential threat to Circassia's product development, approval, and commercialization processes.
- Competitors in the respiratory and autoimmune disease markets are continually launching new products and therapies, creating a competitive threat to Circassia's market share.
- Changes in healthcare policies and reimbursement systems, such as pricing pressures and insurance coverage, could impact the demand and pricing of Circassia's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.